chen, chenyan – page 9 – eisai china lnc.-威尼斯人888

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that a joint research group including scientists from eisai and professor yoshito kishi’s group of harvard university has achieved a total synthesis and obtained results of nonclinical studies of the novel compound, e7130, derived from total synthesis of halichondrin. these results have been published in scientific reports, a scientific journal of nature.1 currently a phase i study to investigate e7130 in solid tumor is underway in japan.

eisai co.,ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) today announced that latest information on lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multiple sleep-wake disorders, including insomnia and irregular sleep-wake rhythm disorder (iswrd) will be presented at the 33rd annual meeting of the associated professional sleep societies (sleep 2019), from june 8 to 12 in san antonio, texas, the united states.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announces today that its u.s. subsidiary eisai inc. has bought out purdue pharma l.p.’s rights in the worldwide collaboration for the development and commercialization of lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multiple sleep-wake disorders, including insomnia and irregular sleep-wake rhythm disorder (iswrd) in patients with alzheimer’s disease. eisai group will solely conduct the development and the commercialization of lemborexant globally.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that in the 8th meeting of the data safety monitoring board (dsmb) for the global phase iii clinical studies (mission ad) on the investigational oral bace (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: e2609) in early alzheimer’s disease (ad), the dsmb reviewed safety data including the potential for decline in cognition, and recommended the continuation of the studies. elenbecestat is being jointly developed by eisai and biogen inc. (headquarters: cambridge, massachusetts, united states).

tokyo and stamford, conn. – march 12, 2019 – eisai co., ltd. (ceo: haruo naito, “eisai”) and imbrium therapeutics l.p. (imbrium therapeutics), a clinical-stage biopharmaceutical company and operating subsidiary of purdue pharma, l.p. (president and ceo: craig landau, md) today announced that the u.s. food and drug administration (fda) has accepted for review the new drug application (nda) for lemborexant, an investigational agent being studied for the treatment of insomnia, a sleep-wake disorder. a prescription drug user fee act (pdufa) date is set for december 27, 2019.